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ABSTRACT
Neurofibromatosis type 1 (NF1) is a relatively common tumour predisposition 
syndrome related to germline aberrations of NF1, a tumour suppressor gene. The 
gene product neurofibromin is a negative regulator of the Ras cellular proliferation 
pathway, and also exerts tumour suppression via other mechanisms. 
Recent next-generation sequencing projects have revealed somatic NF1 
aberrations in various sporadic tumours. NF1 plays a critical role in a wide range 
of tumours. NF1 alterations appear to be associated with resistance to therapy and 
adverse outcomes in several tumour types. 
Identification of a patient’s germline or somatic NF1 aberrations can be 
challenging, as NF1 is one of the largest human genes, with a myriad of possible 
mutations. Epigenetic factors may also contribute to inadequate levels of 
neurofibromin in cancer cells.
Clinical trials of NF1-based therapeutic approaches are currently limited. 
Preclinical studies on neurofibromin-deficient malignancies have mainly been on 
malignant peripheral nerve sheath tumour cell lines or xenografts derived from NF1 
patients. However, the emerging recognition of the role of NF1 in sporadic cancers 
may lead to the development of NF1-based treatments for other tumour types. 
Improved understanding of the implications of NF1 aberrations is critical for the 
development of novel therapeutic strategies.
INTRODUCTION
Neurofibromatosis type 1, also known as NF1 or 
von Recklinghausen’s disease, is a tumour predisposition 
syndrome characterized by the development of multiple 
neurofibromas, café-au-lait spots and Lisch nodules. 
Initially described by Professor Von Recklinghausen, a 
German pathologist back in 1882, NF1 is one of the most 
common genetic disorders worldwide [1, 2]. The NF1 
gene is a classic tumour suppressor gene on chromosome 
17. Its product neurofibromin is an important negative 
regulator of Ras cellular proliferation pathways [3-7]. 
Individuals with NF1 are at increased risk of developing 
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various tumours, including malignant peripheral 
nerve sheath tumour (MPNST), phaeochromocytoma, 
leukaemia, glioma, rhabdomyosarcoma and breast cancer 
[8, 9]. Neurofibromatosis type 1 or NF1 is distinct from 
neurofibromatosis type 2 (NF2), which is less common. 
NF2 syndrome is related to mutations in NF2 on 
chromosome 22, with a different spectrum of tumours, 
notably schwannomas, meningiomas and ependymomas 
[10].
More recently, somatic NF1 aberrations have 
been increasingly reported in various sporadic tumours, 
including brain, lung, breast, ovarian tumours and 
melanomas. Significant challenges remain in the detection 
of both germline and somatic aberrations. A better 
understanding of the implications of these aberrations is 
critical for the improvement of treatment outcomes of 
tumours with NF1 aberrations. 
NF1 syndrome
NF1 is a relatively common genetic condition, with 
an incidence of approximately 1 in 2,000 to 1 in 5,000 
individuals worldwide [2]. Although it is an autosomal 
dominant genetic disorder, approximately half of the cases 
have no family history, with the condition arising from 
sporadic mutations of the NF1 gene. The germline NF1 
mutation rate is ten-fold higher than that observed in other 
inherited disease genes, with estimates from 1/7,800 to 
1/23,000 gametes [2, 11].
The condition has 100% penetrance but its degree 
of expression varies considerably, even within the same 
family with the identical mutation [12]. NF1 is diagnosed 
clinically for most patients, with genetic testing reserved 
for equivocal cases or in the context of research studies. 
The National Institutes of Health (NIH) diagnostic criteria 
stipulate that at least 2 of the criteria in Table 1 must be 
fulfilled to make the clinical diagnosis of NF1 [13].
Loss-of-function mutations in the NF1 gene can also 
lead to the development of a wide range of abnormalities 
in the cardiovascular, musculoskeletal and nervous 
systems, in addition to the predisposition to benign and 
malignant tumours. Hypertension, vasculopathy, valvular 
dysfunction, skeletal anomalies, dysmorphic features, 
osteoprorosis, cognitive impairment and epilepsy may 
occur as part of the NF1 syndrome [14].
The NF1 phenotype is highly variable, ranging 
from a very mild manifestation of the disease in certain 
individuals, to a very severe form in some others [12]. 
In general, there is no definite correlation between a 
particular alteration and phenotype. Exceptions include 
deletion of the entire NF1 gene which is associated with a 
severe form of the disease [15], a recurrently ascertained 
3-bp in-frame deletion of exon 17 (c.2970-2972 delAAT) 
that is associated with the typical pigmentary NF1 features 
but without cutaneous or surface plexiform neurofibromas 
[16], and duplication of the NF1 locus which usually leads 
to intellectual impairment and epilepsy without the other 
NF1 features [17, 18]. Intra- and interfamilial variation 
in severity of the phenotype suggests that expression of 
the same genotype may be influenced by epigenetic or 
environmental factors [12, 19]. Females with NF1 often 
experience an exacerbation of the condition following 
pregnancy, possibly related to changes in the hormonal 
milieu [20].
This overview will focus on mainly the oncological 
aspects of NF1 aberrations, given the recent discovery of 
somatic NF1 aberrations in various cancers in individuals 
without germline NF1.
Biology of NF1 and neurofibromin
Identified and cloned in 1990, the NF1 gene is 
located at chromosome 17q11.2 [4, 21], and is one 
of the largest genes in the human genome, with 60 
exons spanning over 350kb of genomic DNA [4, 22]. 
Another distinctive feature of the gene is the presence 
of 3 genes in intron 27b on the antisense strand: OMGP 
(oligodendrocyte-myelin glycoprotein), a membrane 
glycoprotein, and EVI2A and EVI2B (ecotropic viral 
integration sites), which are involved in the development 
of mouse leukemia [23, 24].
NF1 encodes the protein neurofibromin, which has 
an estimated molecular mass of 327kDa and consists 
of 2818 amino acids. Neurofibromin is ubiquitously 
expressed, but most highly in the central nervous system, 
especially in neurons, astrocytes, oligodendrocytes and 
Schwann cells [25]. As might be expected for such a large 
gene, alternate exons, splice variants and alternate start 
sites have been reported. The major reported functional 
isoforms are derived from the insertion of extra exons that 
       Table 1: National Institutes of Health (NIH) diagnostic criteria for neurofibromatosis type 1 (NF1)
• Six or more café-au-lait macules >5mm in greatest diameter in prepubertal individuals, and >15mm in postpubertal 
individuals
• Two or more neurofibromas of any type or one plexiform neurofibroma
• Freckling in the axillary or inguinal regions
• Optic glioma
• Two or more iris hamartoma (Lisch nodules)
• Distinctive bony lesion such as sphenoid dysplasia, or thinning of the long bone cortex with or without 
pseudoarthrosis
• A first-degree relative (parent, sibling or offspring) with NF1 based on the above criteria
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preserve the open reading frame and show tissue restricted 
expression.
The two major isoforms are neurofibromin types I 
and II. Neurofibromin type I is expressed predominantly 
in the brain, and has significant Ras regulatory activity. 
Neurofibromin type II, also known as GRD2 (domain II-
related GAP) is the product of the insertion of exon 23a. 
In contrast to neurofibromin type 1, it has limited GAP 
regulatory function [26, 27]. It is expressed mainly in 
Schwann cells, and is essential for learning and memory 
in mouse models. In studies on sporadic colon, ovarian 
and breast cancers as well as gastric cancer cell lines, 
expression of the type I isoform relative to type II isoform 
is increased in tumour samples compared to normal tissue 
[28-31].
Information on other neurofibromin isoforms is 
limited. Neurofibromin types III and IV, which contain 
exon 48a and both exons 23a and 48a respectively, are 
expressed in mainly cardiac and skeletal muscles. They 
appear to be essential for normal muscle and cardiac 
development [32, 33]. Apart from neurofibromin types 
I-IV, two other isoforms have been described. An isoform 
which contains exon 9a is expressed mainly in neurons of 
the forebrain, and may be involved in memory and learning 
mechanisms [34, 35]. Another isoform has alternative exon 
10a-2 inserted, introducing a transmembrane domain. The 
function of this variant, which is observed in a majority of 
human tissues, is unclear, but may perform a housekeeping 
function in intracellular membranes [36].
Roles of NF1 and neurofibromin in tumour 
suppression
NF1 is considered a classical tumour suppressor 
gene, with both copies of the NF1 gene reported to be 
inactivated in benign and malignant tumours in NF1 
patients [37-39]. The first hit is inherited or acquired 
as a germline mutation, and the second hit occurs from 
a somatic event. Loss of heterozygosity (LOH) due to 
large somatic rearrangements, deletions and somatic 
recombination may affect the wild-type NF1 allele. This 
can also potentially affect other genes on chromosome 
17, which include the tumour suppressor protein p53 
at 17p13.2, human epidermal growth factor receptor 2 
(HER2) at 17q21.1, topoisomerase II alpha (TOP2A)
(17q21.1), signal transducer and activator of transcription 
3 (STAT3)(17q21.2) and breast cancer gene 1 (BRCA1 )
(17q21.2) [40].
Various Nf1+/- mouse models show predisposition 
to tumour formation, including phaeochromocytomas, 
leukaemias and malignant peripheral nerve sheath tumours 
(MPNST), similar to the spectrum of NF1-associated 
malignancies observed in human counterparts [41-43].
The tumour suppressor function of neurofibromin is 
largely attributed to a small central region which comprises 
360 amino acids encoded by exons 20-27a. This critical 
region has marked structural and sequence similarity to 
ras-guanosine-triphosphate(GTP)ase activation proteins 
(GAPs) and is known as the GAP-related domain (GRD). 
GAPs inactivate Ras by accelerating the conversion of 
active Ras-GTP to its inactive guanosine diphosphate 
(GDP)-bound form. The downregulation of oncogene 
Ras by neurofibromin prevents the downstream activation 
of mitogen-activated protein kinase (MAPK) and the 
PI3K/Akt/mTOR (mammalian target of rapamycin) cell 
proliferation and differentiation pathways, as demonstrated 
Figure 1: The role of NF1 and neurofibromin in the 
Ras pathway. G-protein coupled receptors (GPCRs) and 
receptor tyrosine kinases (RTKs), when activated by ligand, 
promote guanine nucleotide exchange to form activated Ras-
GTP complex. Neurofibromin inactivates Ras by accelerating the 
conversion of active Ras-GTP to inactive GDP-bound Ras with 
its Ras-GTPase activity. Consequently, neurofibromin suppresses 
activation of the downstream effectors of Ras, including PI3K, 
Akt, mTOR, S6 kinase and RAF, MEK, ERK as well as RAC1 
and PAK1. RTKs=receptor tyrosine kinases. Grb2=growth 
factor receptor bound 2. SOS=mammalian homolog of the 
Drosophila son of sevenless. RAS=rat sarcoma viral oncogene 
homologue. GDP=guanosine diphosphate. GTP=guanosine 
triphosphate. RAF=murine sarcoma viral oncogene homologue. 
MEK=MAPK-ERK kinase. PI3K=phosphatidylinositol-3–
kinase. AKT=V-akt murine thymoma viral oncogene homologue 
1. mTOR=mammalian target of rapamycin. Rac1=Ras-related 
C3 botulinum toxin substrate 1. PAK1=P21-Activated Kinase.
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in Figure 1 below [3, 5-7, 44].
The Ras-GAP function of neurofibromin may be 
enhanced by protein kinase C (PKC) phosphorylation 
of the cystein-serine rich domain (CSRD) of the 
neurofibromin domain encoded by exons 11-17. The 
clustering of missense mutations in these regions 
among NF1 patients indicate the importance of PKC 
phosphorylation in sustaining normal neurofibromin 
function [14, 45-48].
Neurofibromin has also been demonstrated to bind 
to caveolin-1 (Cav-1), a membrane protein which regulates 
signalling molecules such as p21ras, protein kinase C and 
growth factor receptors. Formation of the neurofibromin-
Cav-1 complex may lead to inactivation of p21ras-GTP 
and modulation of the p21ras/MAPK, PI3K/Akt pathways, 
controlling cell proliferation and differentiation [14, 49]. 
Apart from downregulation of Ras via the homology 
to GAPs, there are several other postulated mechanisms 
for the tumour suppressor function of neurofibromin 
(Table 2).
Neurofibromin is a positive regulator of the enzyme 
adenylyl cyclase (AC), which generates intracellular 
cyclic AMP (cAMP). cAMP-dependent signaling appears 
to be important in learning and memory, but also provides 
a possible mechanism for tumour suppressor function 
as it regulates Ras activity [50, 51]. Increased cAMP 
leads to activation of Rap1, an anti-mitogenic RAS 
pathway antagonist, which can result in inhibition of 
RAF activation in astrocytes [52, 53]. cAMP-mediated 
regulation of MAPK may have differential effects in 
different tissues; the mechanisms of cAMP-mediated 
tumorigenesis in tissues outside the nervous system have 
not yet been elucidated.
Neurofibromin has also been reported to exert 
tumour suppressor function via a proapoptotic effect by 
Ras-dependent and Ras-independent pathways. Nf1-/-, 
Nf1+/-, and Nf1+/+ mouse embryonic fibroblasts (MEFs) 
exhibited gene-dosage-related resistance to apoptosis. 
Neurofibromin-deficient MEFs and human NF1 malignant 
peripheral nerve sheath tumour (MPNST) cells were more 
resistant to apoptosis than neurofibromin-expressing 
MEFs and schwannoma cells. Administration of 
farnesylthiosalicyic acid (FTS), a Ras inhibitor, increased 
apoptosis of the neurofibromin-deficient SV40 MEFs and 
MPNST cells, indicating dependence on the Ras pathway. 
However, the resistance of neurofibromin-deficient SV40 
MEFs and MPNST cells to staurosporine (protein kinase 
C inhibitor which induces apoptosis), UV irradiation, 
and vincristine was independent of Ras and cAMP, as 
demonstrated by the inability of Ras inhibitors or agents 
that elevate cAMP levels to overcome the resistance. 
Expression levels of key apoptotic components such as 
Bcl-2 family proteins, caspases and the X-linked inhibitor 
of apoptosis (XIAP) were similar in neurofibromin-
expressing and neurofibromin-deficient MEFs. The exact 
mechanism of the Ras-independent proapoptotic effects of 
neurofibromin remains unclear [54]. 
 The role of neurofibromin in cell motility is 
important not only for the functioning in neurons, but 
may also contribute to its tumour suppressor function. 
Neurofibromin regulates the dynamics and reorganisation 
of actin filaments via the Rho-ROCK-LIMK2-cofillin 
pathway, and may be involved in adhesion and signalling 
at neuronal synapses through its interaction (via its GRD 
and C-terminal domains) with the transmembrane heparin 
sulphate proteoglycan syndecan. Lack of neurofibromin 
triggers the Rho-ROCK-LIMK2-cofilin pathway to alter 
the organization of actin cytoskeleton, promoting cell 
motility, invasiveness, and cell-cell adhesion, resulting 
in the formation of large cell aggregates. This may 
lead to the formation of multiple neurofibromas in NF1 
patients, which consist of aggregates of various cell types, 
including Schwann cells, fibroblasts, endothelial cells 
and mast cells on a background of excessive extracellular 
matrix deposition [55, 56]. 
Another mechanism of tumour suppression by 
neurofibromin relates to its association with the N-terminal 
of focal adhesion kinase (FAK), a protein localised at 
contact sites of cells with extracellular matrix known as 
focal adhesions. This interaction helps to regulate cellular 
events including adhesion, proliferation, motility, cellular 
migration and survival. Nf1+/+ mouse embryonic fibroblast 
(MEF) cells exhibited less growth under serum deprivation 
conditions with reduced adherence on collagen and 
fibronectin-treated plates, compared to Nf1–/– cells [57]. 
There is also data to suggest that loss of 
neurofibromin leads to epithelial-mesenchymal transition 
(EMT). EMT is implicated in tumorigenesis and cancer 
metastasis. Immunohistochemical analysis and real-
time quantitative reverse transcription polymerase chain 
reaction showed increased expression of EMT-related 
transcription factors including Snail, Slug, Twist, ZEB1 
and ZEB2 in NF1-associated neurofibroma specimens 
and NF1-derived Schwann cells. Knockdown of NF1 
with siRNA induced the expression of these transcription 
factors in normal human Schwann cells as well as 
epithelial-like breast cancer cell lines [58].
More recently, loss of NF1 has been reported to 
promote carcinogenesis by activating heat shock factor 
1 (HSF1), the master transcriptional regulator of the heat 
shock response. Knockout of NF1 in MEFs triggered 
Table 2: Mechanisms of Tumour Suppression by 
Neurofibromin
Mechanisms of Tumour Suppression Reported
• Downregulation of Ras
• Positive regulation of adenyl cyclase (AC)
• Pro-apoptotic effect (ras-dependent and ras-
independent)
• Regulation of cell adhesion and motility
• Suppression of epithelial mesenchymal transition 
(EMT)
• Suppression of heat shock factor (HSF)
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activation of HSF1, increasing HSF1 levels. This resulted 
in Nf1–/– cells becoming tolerant to proteotoxic stress with 
proteasome inhibitors and HSP90 inhibitor. This activation 
of HSF1 relied on dysregulated MAPK signaling. HSF1, 
in turn, supported MAPK signaling. In NPcis+/- mouse 
models where Trp53 and Nf1 genes are disrupted on 
the same chromosome to develop soft tissue sarcomas 
resembling human MPNSTs, Hsf1 knockout impeded 
NF1-associated carcinogenesis by attenuating oncogenic 
RAS/MAPK signaling. In cell lines from human malignant 
peripheral nerve sheath tumors (MPNSTs) driven by NF1 
loss and in surgically excised human MPNSTs, HSF1 was 
also overexpressed and activated or phosphorylated [59]. 
Tumours associated with NF1
Individuals with NF1 are predisposed to developing 
both benign and malignant tumours throughout life. The 
risk of malignancy is increased 2.5 to fourfold in NF1 
compared to the general population [8, 60]. Average life 
expectancy is reduced by 10-15 years, with cancer being 
the most common cause of death [2]. 
The tumour types individuals with NF1 are at 
increased risk of developing include both nervous system 
and non-nervous system tumours. The characteristics of 
the more common NF1-associated tumours are listed in 
Table 3. Accurate estimation of the relative frequencies 
of the various tumour types is challenging, as different 
studies based on hospital data may overestimate the 
frequency of specific tumours compared to population-
based studies. This partly accounts for the wide range of 
prevalence or incidence figures reported in the literature 
for various tumours.
Malignant peripheral nerve sheath tumours 
(MPNSTs), previously referred to as neurofibrosarcomas, 
are a major cause of morbidity and mortality in NF1. 
MPNSTs typically arise from malignant transformation of 
plexiform neurofibromas, and occasionally spinal nerve 
root or subcutaneous neurofibromas. In NF1 the lifetime 
risk of developing MPNST is 8-13%, with estimated 
annual incidence at 0.16%, compared to 0.001% in the 
general population [9, 61, 62]. 
There is a wide range of other NF1-associated 
tumours including optic pathway gliomas (OPGs), 
rhabdomyosarcomas, neuroblastomas and juvenile 
myelomonocytic leukaemias (JMML) in the paediatric 
setting, as well as gastrointestinal stromal tumour 
(GIST), phaeochromocytomas and carcinoid tumours in 
adults. OPGs, like MPNSTs, may occur in both children 
and adults [9, 61, 62]. More recently, an increased risk 
of breast cancer among women with NF1 has also been 
reported [63, 64]. Breast cancer in NF1 patients appears 
to have an aggressive phenotype in the two reported case 





category Frequency Mechanism(s) 
Differences compared to 
sporadic tumours References
Malignant peripheral 





LOH of NF1, mutation 
in TP53, copy number 
alterations, including deletion 
of CDKN2A, loss of PTEN
Earlier onset; central rather 
than peripheral location











LOH of NF1, mutation in 
TP53, deletion of CDKN2A
Earlier onset; anterior 
rather than posterior optic 
pathway
[9, 61, 62] 
Rhabdomyosarcoma Paediatric Prevalence 1.4-6% unknown
Earlier onset; urinary tract 
rather than head and neck
[9, 61, 81] 
Neuroblastoma Paediatric Unknown
LOH of NF1, amplification of 













Adult Lifetime risk 6%
LOH of NF1, some copy 
number alterations
Small intestine and multiple 
rather than gastric origin; 
lack of response to imatinib 
with lack of KIT and 
PDGFRA mutations
[9, 61, 87, 88] 
Phaeochromocytoma Adult Prevalence 1% LOH of NF1 Earlier onset; occasionally 
bilateral or extradrenal
[9, 61, 62, 89-91] 
Carcinoid Adult Prevalence 1% LOH of NF1 Earlier onset; periampullary 
rather than small intestine
[61, 62, 92] 
Breast Cancer Adult
Standardised 
incidence ratio of 
3.5 to 5.2
Unknown





NF1 patients are also at an increased risk of 
developing radiation-induced malignancies. In a study of 
NF1 patients treated with radiotherapy for optic glioma, 
the relative risk of second CNS tumour was 3.04 (95% CI, 
1.29 to 7.15) [67]. Hence radiotherapy should be avoided 
in children with NF1, unless it is absolutely essential. In 
mouse model studies, Nf1+/- mice subjected to irradiation 
developed in-field tumours associated with NF1 such as 
phaeochromocytomas, as well as typical second malignant 
neoplasms such as sarcomas and breast cancers [68-70]. 
This may be related to upregulated, perturbed cell cycle 
and DNA repair pathways with NF1-haploinsufficiency, 
as observed in human lymphoblastoid cell lines from NF1-
affected and normal individuals, as well as in lymphocytes 
from wildtype and Nf1+/- mice. Activation of DNA 
damage response (DDR) genes can paradoxically trigger 
oncogene-induced DNA damage and genomic instability, 
resulting in carcinogenesis [71, 72]. Interestingly, somatic 
monoallelic loss of NF1 and TP53 in the adjacent allele 
was observed in radiation-induced malignancies arising 
in both wildtype and Nf1+/- mice in one study [68]. NF1 
loss appears to be a critical event in mutagen-induced 
malignancies beyond the classical NF1-associated tumour 
types.
Somatic NF1 Aberrations in Sporadic Tumours 
and Effects of NF1 Deficiency
With the recent cancer genome sequencing projects, 
the heterogeneity of cancer genomes has been unraveled. 
Somatic NF1 aberrations are increasingly reported in 
various sporadic tumours, including brain, lung, breast, 
ovarian tumours as well melanomas and leukemias (Figure 
2). This is particularly relevant with the advent of novel 
molecular therapies which can potentially be targeted at 
aberrations in the NF1 pathway. Improved understanding 
of the mechanisms of carcinogenesis is critical for the 
optimisation of these targeted therapies.
Brain Tumours
In glioblastoma multiforme (GBM), NF1 is one 
of the most frequently mutated or deleted genes. The 
prevalence of NF1 somatic mutations in sporadic GBMs 
was initially estimated to be approximately 15%, with a 
subsequent study by The Cancer Genome Atlas (TCGA) 
network reporting aberrations in at least 23% (47 out of 
206) of human GBM samples when both NF1 inactivating 
mutations and deletions (including heterozygous deletions) 
were analysed [93, 94]. However, when only mutations 
and homozygous deletions are considered, the frequency 
of alterations ranges from 12.1 to 17.6% [94, 95]. 
Data from mouse models support the importance of 
NF1 as a glioblastoma suppressor gene. Inactivation of 
TP53 and PTEN may cooperate with NF1 loss to induce 
the malignant transformation [96]. Haploinsufficiency 
for the NF1 tumour suppressor may have functional 
consequences, such as increased astrocyte proliferation 
and augmentation of angiogenesis in Nf1+/- heterozygous 
mouse models [97, 98]. Integrated genomic analysis of 
the TCGA data identified GBMs with NF1 and PTEN 
alterations to have a distinct mesenchymal-like expression 
profile. This mesenchymal subtype was characterised by 
the expression of mesenchymal markers such as CHI3L1 
(also known as YKL40) and MET, as well as astrocytic 
markers (CD44, MERTK), reflecting the epithelial-to-
mesenchymal transition. There was also high expression 
of genes in the tumour necrosis factor (TNF) and NK-ĸB 
pathway, related to the greater necrosis and associated 
inflammatory response in this subtype [99, 100].
Melanoma
Loss of NF1 in malignant melanoma cell lines 
was reported soon after discovery of the NF1 gene in 
the early 1990s [101, 102], but it was only recently that 
comprehensive genomic characterization of melanomas 
was performed. Melanomas may be classified into 3 major 
classes: 1) sun-shielded melanomas with wild type BRAF 
and NRAS which have low mutation load but high number 
of copy gains, 2) sun-exposed melanomas with BRAF or 
NRAS mutations and 3) sun-exposed melanomas with 
wild-type BRAF and NRAS, few copy number alterations 
but high mutation load. The last subtype of melanoma was 
typically associated with more advanced age, and 30% 
of melanomas from this class (10/33 samples) carried 
deleterious NF1 mutations. TP53, ARID2 and PTPRK 
were frequently mutated in these melanomas, suggesting 
that inactivation of tumour suppressors contribute to 
the pathogenesis of these BRAF and NRAS independent 
tumours [103, 104]. The overall frequency of NF1 
mutations is estimated at 14% of cutaneous melanomas, 
with total of 475 specimens analysed so far in 3 separate 
studies (Figure 2) [103, 105].
Somatic NF1 mutations have also been reported in 
melanoma specimens harboring BRAF mutations [105, 
106]. In a mouse model study, NF1 mutations cooperate 
with BRAF mutations in the pathogenesis of melanomas 
by preventing oncogene-induced senescence [106]. Loss 
of neurofibromin expression and NF1 loss-of-function 
mutations have been reported in melanomas from patients 
with de novo as well as acquired resistance to BRAF 
inhibitors [106, 107]. A pooled RNA interference screen 
targeting >16,500 genes in a BRAF inhibitor-sensitive 
melanoma cell line identified NF1 as the highest ranking 
gene whose knockdown abrogated the growth inhibitory 
effects of PLX4720, a BRAF inhibitor [107]. NF1-mutant 
melanomas are unlikely to respond to standard BRAF-
targeted therapies but may benefit from drugs targeting the 
MEK and PI3K pathway instead. In mice injected with 
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BRAF/NF1-mutated melanoma cells, there was resistance 
to vemurafenib, a BRAF inhibitor. In contrast, there was 
greater sensitivity to MEK inhibitor PD0325901, PI3K 
inhibitor GDC-0941 and rapamycin, an mTOR inhibitor. 
Importantly, rapamycin synergized with PD0325901, 
resulting in tumour regression in the allografts [106].
Lung Cancer
Whole exome or genome sequencing of primary 
lung adenocarcinomas identified NF1 as one of the most 
frequently mutated genes, with an estimated frequency 
of 11-12% [108, 109]. The clinical significance of NF1 
mutations in the lung adenocarcinoma sequencing studies 
is not reported, but reduced NF1 mRNA expression 
was recently found to confer both intrinsic and acquired 
resistance to EGFR inhibitors in another recently reported 
study. However, somatic NF1 mutations were not found in 
the specimens from these patients with resistant tumours 
(more details in section on challenges of molecular 
diagnosis of NF1 and NF1 somatic aberrations) [110].
Approximately 12% of squamous cell lung cancers 
have alterations in NF1, according to a recently published 
TCGA study on squamous cell carcinomas. mRNA 
expression profiling identified 4 distinct subtypes of 
squamous cell lung cancers – classical, primitive, basal 
and secretory expression subtypes. The basal expression 
subtype of squamous cell lung carcinoma characteristically 
showed alterations in NF1 [111]. 
There is less data on small cell lung cancer, but the 
frequency of mutations in NF1 was reported as 2.4% and 
6.9% in two separate studies of a smaller scale [112, 113]. 
Ovarian Carcinoma
The importance of NF1 in ovarian cancer was 
first reported by Sangha et al [114]. Initial genome-wide 
screen of DNA copy number alterations (CNAs) identified 
apparent NF1 homozygous deletions in 2 out of 36 primary 
ovarian serous carcinomas. This led to the discovery that 
6 out of 18 ovarian carcinoma-derived cell lines had 
markedly reduced or lacked expression of NF1 protein, 
with 5 of the 6 cell lines harbouring NF1 mutations. 
Alterations in NF1, including splicing mutations and 
homozygous deletions, were identified in 22% (9/41) of 
the primary ovarian serous carcinomas studied. There was 
evidence of Ras pathway activation in these tumours and 
cell lines with NF1 defects, in the absence of KRAS or 
BRAF mutations. NF1 appears to cooperate with TP53 
mutations which are present in virtually all ovarian serous 
carcinomas, in carcinogenesis [114].
In the large scale integrated genomic analyses of 
489 high grade serous ovarian carcinomas by the TCGA 
cooperative group, NF1 has been recognized as one of the 
most frequently altered genes, with aberrrations in 12% 
of the cases (8% homozygous deletions, 4% mutations) 
[115]. These alterations affect signaling in the PI3K/
Ras pathway, and may have therapeutic implications as 
discussed later in this review.




Although a computational biology study on gene 
expression datasets had previously reported associations 
between the activity levels of regulatory pathways linked 
with NF1 to clinical outcome in breast cancer [116], the 
importance of NF1 in the pathogenesis of breast cancer 
was not investigated further until recently. Absence of 
neurofibromin protein and lack of expression of NF1 
mRNA type 1 isoform have been reported in the highly 
aggressive human breast cancer MDA-MB-231 cell line 
which is resistant to endocrine and cytotoxic agents. This 
was associated with accumulation of phosphorylated 
MAPK and activated Ras [117]. More recently, this 
Claudin-low subtype cell line was found to harbour NF1 
mutation [118]. The Cancer Genome Project led by the 
Sanger Institute and The Cancer Genome Atlas (TCGA) 
projects reported NF1 mutations in approximately 3% of 
the breast cancers sequenced. Proportionally more NF1 
mutations were found in luminal or ER+HER2- subtypes, 
although they were also present in selected HER2-
overexpressing and triple negative or basal tumours [119, 
120]. This may have therapeutic implications, given that 
knockdown of NF1 in MCF7 cells conferred resistance to 
tamoxifen in a genome-wide functional study [121].
NF1 has also been implicated as a breast cancer 
driver in a recent mouse model study. Chaos3 mice, 
which are engineered with a point mutation in the 
minichromosome maintenance 4 (Mcm4) gene, are 
highly unstable genomically, leading to the development 
of mammary tumours which resemble human breast 
cancers [122]. NF1 was found to be deleted in nearly 
all the mammary tumours from these mouse models. 
This led to re-examination of the TCGA data. 27.7% 
of human breast cancers in the TCGA project were 
subsequently found to harbour NF1 aberrations, majority 
of which were heterozygous deletions. Over 40% of 
HER2-overexpressing and basal subtypes showed these 
aberrations. This highlights the importance of investigating 
for the loss of NF1, in addition to the mutations [122].
Loss of heterozygosity of NF1 has been detected 
in radiation-induced breast cancers from patients without 
NF1 syndrome. The monoallelic loss of NF1 is likely to 
increase the potential for cooperating with other pathways 
such as TP53 pathways to promote cellular proliferation 
and carcinogenesis [68]. Loss of NF1 gene has also been 
reported in malignant phyllodes tumour of the breast [123] 
.
Haematological Malignancies
NF1 was previously implicated as one of the 
important drivers in certain sporadic haematological 
malignancies. Myeloid malignanices frequently harbor 
mutations in the Ras pathway. It is likely that NRAS/KRAS/
NF1 aberrations cooperate with mutations in transcription 
factors and genes that regulate the epigenome in complex 
events leading to the development of AML [124]. In 
earlier studies, NF1 mutations were reported in up to 7% 
of acute myeloid leukemia (AML) cases, while 12% of 
95 cases studied had copy number alterations in NF1 with 
mainly heterozygous deletions. Complete absence of NF1 
expression was reported in 7% of adult AML, and this 
was associated with increased Ras-bound GTP [125]. In 
another study on a subset of AML with CBFB–MYH11 
rearrangements, 16% of cases showed deletion of NF1 
[126]. However, two recent large scale studies suggested 
that NF1 aberrations are not as frequent in de novo AML, 
although it may occur as a secondary event in disease 
progression [127, 128]. After taking into account the size 
of the gene in the test for significantly mutated genes, NF1 
is not one of the significantly mutated genes in AML, with 
the gene altered in 2.7% of 187 cases [128].
Limited data suggests the frequency of NF1 
alterations in myelodysplastic syndrome (MDS) varies 
from 0% to 9% [129, 130]. Recurrent cryptic alterations 
or deletions of the NF1 locus have been detected in 3 out 
of 35 patients in one of the studies [129]. The frequency 
of NF1 mutations in sporadic acute lymphoid leukemia 
(ALL) was recently reported as 3-8% [131, 132]. The 
prevalence of NF1 aberrations in other haematological 
malignancies such as multiple myeloma is currently 
unclear. 
Colorectal Carcinoma
Data on the nature and the frequency of NF1 
aberrations in colorectal carcinoma vary widely. After 
the initial report by Li et al that 1 out of 22 sporadic 
colon adenocarcinomas (4.5%) harboured the amino acid 
substitution altering Lys-1423 in the NF1 GRD [133], loss 
of heterozygosity (LOH) involving the NF1 gene in 14-
57% of colorectal carcinomas was reported in two small 
studies [134, 135]. In addition to NF1 missense mutations, 
Ahlquist et al also found duplication of the whole NF1 
gene or parts of it in 4 out of 24 specimens (17%) [136]. 
Nine out of ten NF1 mutations detected in this study 
occurred in introns likely involved in exon splicing. 
Notably, 8 of these 10 carcinomas showed microsatellite 
instability [136]. In contrast, NF1 was found to be altered 
in approximately 3.8-5.6% of colorectal carcinomas in two 
recent next generation sequencing studies [137, 138].
Other Sporadic Tumours
As displayed in Figure 2; there are several other 
tumours in which NF1 aberrations have been reported.
Aberrations of NF1 have also been reported 
in sporadic soft tissue sarcomas. Up to 10.5% of 
myxofibrosarcomas and 8% of pleomorphic liposarcomas 
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harbor NF1 mutations [139, 140]. In a study on embryonal 
rhabdomyosarcoma, loss of NF1 occurred in 35%(9/26) 
of tumours (heterozygous or homozygous deletion of NF1 
or heterozygous chromosomal loss), and were mutually 
exclusive with Ras mutations, suggesting NF1 loss as 
an alternative and potentially common driver of Ras 
activation in this major subtype of soft tissue sarcoma in 
young children [140].
A few studies reported somatic NF1 aberrations or 
inactivation in 26-41% of sporadic phaeochromocytomas 
from individuals without NF1. In keeping with the 
observation that NF1 individuals are at increased risk 
of developing phaeochromocytomas, these findings 
suggest that loss of NF1 function is a crucial event in 
the pathogenesis of both sporadic and NF1-associated 
phaeochromocytomas [91, 141, 142] . 
Challenges of molecular diagnosis of NF1 and 
detection of NF1 somatic aberrations
The diagnosis of NF1 syndrome is usually 
established clinically in individuals with constitutional 
features of the syndrome. Germline NF1 testing is 
reserved mainly for equivocal cases, for prenatal diagnosis 
and in the research setting. Detection of NF1 mutations or 
deletions can be highly challenging due to several factors. 
NF1 is one of the largest genes, with 60 exons spanning 
over 350kb of DNA. The gene also has one of the highest 
mutation rates, with up to half of the mutations being 
novel mutations. In addition to the myriad of possible 
lesions with more than 1,200 different germline mutations 
reported so far (source: The Human Gene Mutation 
Database; http://www.hgmd.org) and the lack of mutation 
hotspots, the presence of several pseudogenes can 
complicate the molecular diagnosis further [11, 143-147]. 
A multi-step protocol involving analysis of genomic DNA 
and mRNA with RT-PCR, direct sequencing, multiplex 
ligation-dependent probe amplification (MLPA), and 
previously using also microsatellite marker analysis and 
FISH, was required to identify up to 95% of pathogenic 
mutations in individuals fulfilling the clinical NIH 
diagnostic criteria [148-150]. Analysis of RNA is essential 
as splicing mutations may be present in more than 20% of 
individuals with NF1 syndrome [144, 149, 150], and may 
be located deep in introns which may be missed when only 
exons are studied.
Given the potential difficulties of detecting the 
pathogenic mutation in individuals with clinical features 
of NF1, the identification of somatic NF1 aberrations in 
sporadic tumours can also pose a significant challenge. It 
is possible that the frequency of somatic NF1 alterations 
in various tumours is higher than what is currently 
recognized. 
Although next generation sequencing (NGS) may 
be less laborious than direct sequencing, there are also 
limitations with NGS techniques. Decreased specificity of 
the capture probes may lead to the capture and enrichment 
Figure 3: Potential therapeutic strategies for NF1-deficient malignancies. The molecular therapies above have been tested 
in the preclinical setting, largely for MPNSTs. There is also data on some of the inhibitors for neurofibromin-deficient breast cancer, 
glioblastoma, AML, soft tissue sarcoma, lung cancer and melanoma. Combination therapy targeting more than one checkpoint may be 
required for optimal inhibition.
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of off-target sequences, including those from pseudogenes 
and closely related genes [143]. Exome sequencing alone 
may not detect splicing mutations or gene rearrangements. 
Whole genome sequencing combined with transcriptome 
analysis may be superior, but there are limitations to its 
applicability in the clinical setting currently due to the 
general requirement for fresh frozen tissue, complexity of 
data analysis and cost.
Downregulation of NF1 and neurofibromin via 
other mechanisms
Epigenetic factors, such as gene silencing by 
microRNAs and DNA methylation, may also influence the 
expression of NF1 and neurofibromin, as described below. 
microRNAs are endogenous, small noncoding 
RNAs which can influence their target gene expression 
post-transcription. Downregulation of NF1 by microRNA-
193b, which is overexpressed in sporadic head and neck 
squamous cell carcinomas (HNSCC), led to activation 
of ERK and resulted in tumour progression. Survival 
outcomes in HNSCC patients whose tumours expressed 
high levels of miR-193b were inferior compared to 
patients with low miR-193b expression. Knockdown of 
miR-193b in HNSCC cells increased NF1 transcript and 
protein expression levels, decreased ERK phosphorylation 
with reduction in cell viability, migration, invasion and 
tumour formation [151]. 
There is limited data on methylation changes, but 
methylation of NF1 was recently found to be the cause of 
a somatic second-hit inactivation in pilocytic astrocytoma 
from a patient with NF1 [152].
Excessive proteasomal degradation of neurofibromin 
can also result in deficiency of this critical tumour 
suppressor protein [153]. The ubiquitin ligase complex 
which controls both the regulated destruction and 
pathogenic destabilisation of neurofibromin was recently 
identified in glioblastomas as a Cullin 3(Cul3)/kelch 
repeat and BTB domain-containing 7 complex. Inhibition 
of Cul3 with Cul3-specific shRNAs suppressed Ras/
ERK signaling; agents aimed at blocking neurofibromin 
destruction may be a potential therapeutic strategy for 
further development [154]. 
Given that the expression of NF1 may be influenced 
by epigenetic factors, microRNAs [155] and proteasomal 
degradation [153, 154], a proteomics-based approach may 
help to detect deficiency of neurofibromin. The utility of 
immunohistochemical staining of neurofibromin has not 
been fully explored. Complete absence of neurofibromin 
staining on immunohistochemistry was found in 15-18% 
of melanomas [106]. However, quantitation of protein 
expression correlating with treatment outcomes has 
not been well studied. This is also complicated by the 
fact that current antibodies available may not be able to 
distinguish between the normal and mutant neurofibromin 
protein. Functional studies of “mutant neurofibromin” 
will be challenging with the huge protein size and myriad 
abnormalities possible.
The challenges of elucidating the mechanisms of 
NF1 deficiency are demonstrated in the recent study on 
reduced NF1 expression as a driver of resistance to EGFR 
inhibitor in lung cancer. NF1 mRNA expression was 
reduced in EGFR TKI-resistant lung cancer specimens, 
but somatic mutations and methylation changes involving 
NF1 were not detected. To account for the downregulation 
of NF1 mRNA, immunohistochemistry using multiple 
antibodies was performed, but none of them demonstrated 
adequate specificity to detect neurofibromin in human lung 
tissue [110].
Therapeutic Strategies for NF1 and NF1-
associated/deficient malignancies
Management Options for NF1 syndrome and 
neurofibromas
The management of individuals with NF1 consists 
mainly of surgical resection of neurofibromas when 
they cause discomfort or impingement of neighbouring 
structures such as nerves or spinal cord. There is an unmet 
need for novel molecular therapies to treat the systemic 
manifestations in NF1. 
Early clinical trials using thalidomide, 13-cisretinoic 
acid (CRA) or interferon α-2a to target angiogenesis 
and differentiation in NF1 patients with plexiform 
neurofibromas induced at best a minor response in a 
minority of patients [156, 157]. Early phase trials using 
pirfenidone, an antifibrotic agent drug which targets the 
stromal contributions, showed similar limited activity in 
plexiform neurofibromas in adults and children [158, 159].
Since Ras is overactivated with dysfunction of 
NF1, subsequent NF1 trials focused on inhibition of Ras. 
Farnesylation and geranylgeranylation of Ras proteins 
is essential for translocation to the cell membrane with 
subsequent activation of the Ras pathway. The activity of 
tipifarnib, a farnesyl transferase inhibitor, was reported 
in a phase 1 trial on children with solid tumours or NF1 
and plexiform neurofibromas. Stable disease was the best 
response; no significant regressions were observed [160]. 
More recently, in a phase 2 placebo-controlled study on 
children and young adults with NF1 and progressive 
plexiform neurofibromas, tipifarnib did not prolong the 
time to progression compared to placebo [161]. Similarly, 
results from a phase 2 study using sirolimus (rapamycin), 
an mTOR inhibitor, in NF1 patients with plexiform 
neurofibroma, did not report any regression of the lesions 
[162]. Clinical trials using everolimus, a newer generation 
mTOR inhibitor and other therapies are in progress (http://
www.clinicaltrials.gov). The MEK inhibitor PD0325901 
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was effective in shrinking plexiform neurofibromas in 
more than 80% of genetically engineered mice, but data 
on clinical activity in human subjects is awaited [163].
Pegylated interferon-α-2b, which has 
antiproliferative, antiangiogenic and immunomodulatory 
properties, induced minor response in 29% of young 
patients with plexiform neurofibromas in a phase I trial 
[164]. Tumour stabilization or prevention of new lesions 
may be a more realistic endpoint as dramatic regression 
of established “benign” tumours is less likely. Although 
neurofibromas may show LOH in a subset of Schwann 
cells, the mode of pathogenesis is different from that of 
malignant tumours [165]. However, imatinib mesylate, 
an oral kinase inhibitor targeting c-kit and PDGFRβ, was 
recently reported to decrease plexiform neurofibromas by 
20% or more in 6 out of 36 NF1 patients in a phase 2 trial. 
This effect may partially be related to targeting cellular 
phosphor-signalling cascades [166-168]. In contrast, 
sorafenib which targets c-kit and PDGFRβ as well as 
RAF, VEGFR2, was poorly tolerated and did not show any 
tumour response in a phase 1 trial on children with NF1 
and plexiform neurofibromas [169]. The clinical efficacy 
of these compounds in treating neurofibromas remains to 
be tested in larger clinical trials.
Potential therapeutic strategies for NF1-deficient 
malignancies
Data on the efficacy of molecular therapies in NF1-
deficient malignancies is currently limited to results from 
preclinical studies (Figure 3). Much of this research has 
been conducted on models of MPNST derived from NF1 
patients. This is set to change with emerging clinical trials 
where the molecular therapy is matched to the genomic 
profile of each individual’s tumour. A one-size fits all 
approach may not always deliver an optimal outcome. For 
instance, although imatinib is standard-of-care for most 
patients with sporadic GIST, KIT/PDGFRA mutations 
are uncommon in GISTs arising in NF1 individuals, so 
response to imatinib is poor in these patients [88]. 
There is preclinical data to support the activity of 
MEK inhibitors, Ras inhibitor farnesylthiosalicylic acid, 
sirolimus, everolimus and PI3K/Akt/mTOR inhibitors in 
MPNST cell lines or xenografts derived from NF1 patients 
[163, 170-174] (Figure 3). The addition of erlotinib, an 
epithelial growth factor receptor (EGFR) inhibitor to 
everolimus, inhibited growth and induced apoptosis 
further in 4 NF1-derived and 1 sporadic MPNST cell 
lines as well as the STS26T sporadic MPNST xenograft 
[172]. EGFR expression is present in most MPNST cell 
lines, and the EGFR signaling pathways were found to be 
associated with tumorigenesis in the Nf1:p53 mouse tumor 
model [172, 175].
Signal transducer and activator of transcription-3 
(STAT3) is a potential target for treating NF1-associated or 
NF1-deficient cancers, as STAT3 is activated downstream 
in the PI3K/mTOR pathway. The natural product 
cucurbitacin-I, a potent STAT3 inhibitor, was found to 
inhibit the growth of NF1-deficient MPNST cells in vitro 
and in vivo in xenografts [176] .
Since heat shock factor is activated with loss of 
NF1, it is not surprising that the addition of HSP90 
inhibitor IPI-504, to rapamycin, led to synergistic activity 
with damage of endoplasmic reticulum and mitochondria 
in NF1-deficient MPNST mouse models [177].
More recently, integrative transcriptome analyses 
have identified Aurorakinase A(AURKA) as a potential 
therapeutic target. AURKA was overexpressed and 
amplified in NF1-related MPNST, but not neurofibromas. 
MLN8237, an AURKA selective inhibitor, was effective in 
stabilizing tumour volume and prolonged survival of mice 
with MPNST xenografts [178]. 
Inhibitors of PAK1, a downstream effector in the Ras 
pathway, have also been reported to suppress the growth 
of NF1-deficient MPNST cells as well as neurofibromin-
deficient human breast cancer (MDA-MB-231) xenografts 
in mice. There is evidence that many tumours, including 
breast cancers, are addicted to abnormal activation of 
PAK1, a Ser/Thr kinase which in turn stimulates cyclin 
D1, for their growth [179, 180]. 
In sporadic tumours harbouring NF1 aberrations, 
MEK inhibitors have been found to be effective in 
treating neurofibromin-deficient sporadic glioblastoma 
cell lines, NF1-deficient AMLs and NF1-deleted soft 
tissue sarcomas in mouse models [181-183]. Following 
the discovery that NF1 deficiency confers intrinsic and 
acquired resistance to EGFR inhibitor in lung cancer, 
treatment of neurofibromin-deficient lung cancers in vitro 
and in xenografts with MEK inhibitory drugs (AZD-6244, 
CI-1040 and PD0325901) restored sensitivity to erlotinib 
when given in combination [110].
Combination therapies targeting more than one 
checkpoint in the cell proliferation pathway, such as 
blocking both the PI3K/mTOR and MEK pathways in 
the allografts of NF1/BRAF-mutated melanomas and dual 
EGFR, MEK inhibition concurrently in TKI-resistant 
NF1-deficient lung adenocarcinomas, may be superior to 
monotherapy [106, 110]. Inhibiting a single checkpoint 
may lead to activation of compensatory negative feedback 
pathways. 
Future strategies may include inhibition of excessive 
destruction of neurofibromin and other epigenetic 
therapies. In Nf2-mutant Schwann cells, inhibition of 
SIRT2, a class III histone deacetylase, triggered necrosis 
[184]. The role of HDAC inhibitors, which may decrease 
Akt phosphorylation, has not been fully explored for Nf1-
mutant cells. Inhibition of LIM kinase in the Rho-ROCK-
LIMK-cofilin pathway regulated by neurofibromin is 
another potential strategy. In Nf1–/– MEFs, novel LIMK 
inhibitors blocked the phosphorylation of cofilin, resulting 
in actin severance and inhibition of cell migration 
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and growth [185]. The utility of these drugs in NF1-
deficient tumours may be worth investigating, especially 
in combination with Ras or AURKA inhibitors, which 
may have synergistic effects [185, 186]. Improved 
understanding of the biology of NF1 and neurofibromin in 
normal cells and cancer is critical for the development of 
novel treatment strategies. 
CONCLUSIONS 
NF1 and neurofibromin play critical roles in tumour 
suppression. The frequency of somatic NF1 aberrations 
in sporadic tumours is increasingly recognized. These 
alterations are associated with distinct subtypes in certain 
cancers, and may be associated with poorer treatment 
outcomes. Significant challenges remain in unravelling 
the complexity of the large NF1 gene and its product 
neurofibromin. Improved molecular diagnosis techniques 
are essential for detecting these aberrations. There is also 
an unmet need to develop novel systemic therapies for 
treating NF1-deficient tumours.
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